Harry McCann

Mr McCann has Board experience with some of Australia's companies. He is a former corporate lawyer and Chairman and Director of listed private and government companies, and government agencies. Mr McCann's expertise in shaping culture (including through organisational and remuneration design), public policy, social performance and stakeholder engagement, enables him to bring insights in these areas. He previously served as Chairman of Macquarie Group and Macquarie Bank Limited (from December 1996 to March 2016), Origin Energy Limited (from January 2000 to October 2013) and the Sydney Harbour Federation Trust (from June 2001 to June 2010 and from June 2015 to June 2018). He was also previously a Director of Bluescope Steel Ltd (from May 2002 to April 2013) and E&P Financial Group Limited (from February 2020 to November 2021). He was also a Director of the U.S. Studies Centre at the University of Sydney (from June 2010 to June 2020) and was a Trustee of the Sydney Opera House (from January 2018 to December 2023). Currently, Mr McCann is a Member of Champions of Change Founding Group (since April 2010), Chairman of Sydney Harbour Foundation Management (since August 2015), Chairman of China Matters (since November 2018), a Director of Haydn Ensemble (since December 2020), and Chair and Board Advisor of Blueprint Institute (since June 2022). Mr McCann practised as a commercial lawyer as a partner of Allens Arthur Robinson from 1970 to 2004 and was Chairman of Partners from 1995 to 2004. He was made an Officer of the Order of Australia for services to business, corporate governance and gender equality in January 2020. He is member of risk committee and chair of People, Culture and Disclosure Committee.

Company and Roles

Company
Title
Tenure
Since
TLX
Telix Pharmaceuticals Limited
  • Non-Executive Chairman
  • Non-Executive Director
6yrs, 5mthSep 2017

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
TLX
Telix Pharmaceuticals Limited
22/02/241,150,000N/AN/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
TLX
Telix Pharmaceuticals Limited
29/09/21
Buy
990,000$0.850$841,500Exercise of options
TLX
Telix Pharmaceuticals Limited
29/09/21
Exercise
990,000$0.850$841,500Exercise of options